Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations

NCT07120464 is registered in ClinicalTrials.gov with Liaoning Chengda Biotechnology CO., LTD as lead sponsor.

NCT NCT07120464
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07120464 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Immunogenicity and Safety of Lyophilized Vero Cell-Derived Human Rabies Vaccine in Special Populations
Lead sponsor
Liaoning Chengda Biotechnology CO., LTD
Phase
Observational
Overall status
Recruiting
Start date
August 15, 2025
Completion date
December 31, 2026
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic disease, immunocompromised, rabies exposure